Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (RVMD) reported updated Phase 1/2 results for RASONQUE (daraxonrasib) plus chemotherapy as a potential first-line treatment for metastatic pancreatic adenocarcinoma.
As of September 28, 2026, 61 patients in the open-label RMC-GI-102 cohort had received 200 mg of RASONQUE with gemcitabine and nab-paclitaxel. At a median follow-up of 18.3 months, the confirmed tumor response rate was 60.7%, including complete responses in 8.2% of patients. Disease control was 90.2%, and median response duration was 11.1 months. Median progression-free survival was 12.8 months, and estimated 12-month overall survival was 76.6%.
Safety was consistent with the known profiles of both treatments. The combination received FDA Breakthrough Therapy Designation for this first-line setting, and the Phase 3 RASolute 303 trial is ongoing.
Revolution Medicines (RVMD) received European Commission approval for RASONQUE (daraxonrasib) to treat adults with previously treated metastatic pancreatic adenocarcinoma.
The once-daily oral monotherapy is approved after at least one prior systemic therapy, with or without an identified tumor RAS mutation. Authorization covers all EU member states and EEA countries Iceland, Norway and Liechtenstein, but not the United Kingdom or Switzerland.
Approval rests on the Phase 3 RASolute 302 trial comparing RASONQUE with investigator-selected chemotherapy. The trial met all primary and key secondary endpoints in both the RAS G12 mutation population and the overall population. Revolution Medicines is working to enable access; timing depends on country-specific pricing, health-technology assessment and reimbursement processes.
Revolution Medicines (Nasdaq: RVMD) reported third-quarter RASONQUE net product revenue of $197.6 million following its first U.S. approval and commercial launch. The FDA approved the drug on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma previously treated with systemic therapy or unable to receive multiagent systemic therapy. Sales covered approximately five weeks and included initial inventory stocking and patients transitioning from expanded access or awaiting approval; the company cautions against extrapolating this early trajectory.
A positive European regulatory committee opinion supports potential approval, but a European Commission decision remains pending. Cash and marketable securities totaled $3.7 billion at September 30, excluding $250 million of debt proceeds received in October. Research and development expenses were $417.1 million. The company also advanced multiple Phase 3 cancer trials.
Revolution Medicines (RVMD) announced that CEO and chairman Mark A. Goldsmith will participate in two investor conferences in November 2026.
His fireside chats are scheduled for the Guggenheim Healthcare Innovation Conference on November 10 at 8:30 a.m. ET and the Jefferies Global Healthcare Conference in London on November 16 at 5:30 a.m. ET. Live webcasts and replays will be available on the company’s website, with replays accessible for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) presented exploratory Phase 3 analyses showing RASONQUE survival benefits across evaluated subgroups in previously treated metastatic pancreatic cancer. The RASolute 302 findings presented at ESMO 2026 covered tumor RAS profiles, chemotherapy comparators and prior treatment settings, including patients with no identified tumor RAS mutation.
Previously reported median overall survival was 13.2 months with RASONQUE versus 6.7 months with chemotherapy. Subgroup hazard ratios, which compare death rates between treatments, ranged from 0.32 to 0.61 across evaluated RAS profiles; several confidence intervals included 1, leaving uncertainty about those subgroup effects. RASONQUE is approved in the United States. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion, but the drug remains investigational outside the United States.
Revolution Medicines (RVMD) will report third-quarter 2026 financial results after market close on November 4, 2026. Senior management will host a webcast at 4:30 p.m. ET that day to discuss the results and provide an update on corporate progress. A replay will be available on the company’s website for at least 14 days.
Revolution Medicines (RVMD) has begun treating patients in a Phase 3 trial testing zoldonrasib with pembrolizumab and chemotherapy for metastatic lung cancer. The global RASolve 308 trial enrolls adults with previously untreated metastatic RAS G12D non-squamous non-small cell lung cancer. Zoldonrasib is an investigational drug designed to inhibit the active form of RAS G12D.
The randomized, double-blind study compares zoldonrasib plus pembrolizumab and a platinum-based chemotherapy doublet against placebo plus the same standard treatments. Its primary endpoint is progression-free survival, measuring time without cancer worsening or death. Revolution Medicines described earlier combination data in this patient population as showing encouraging preliminary antitumor activity and a favorable safety profile.
Revolution Medicines (RVMD) received a positive CHMP opinion recommending EU authorization of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma. The recommendation covers once-daily oral daraxonrasib alone after at least one prior systemic therapy; European Commission approval remains pending.
The opinion followed expedited review under the EMA’s Cancer Medicines Pathfinder project and Phase 3 RASolute 302 results. The trial met all primary and key secondary endpoints in both the RAS G12 mutant and overall study populations. In the overall population, RASONQUE reduced the risk of death by 60% versus chemotherapy. Median overall survival was 13.2 versus 6.7 months, and median progression-free survival, the time before disease worsens or death, was 7.2 versus 3.6 months. Common adverse reactions included diarrhea and acne-like dermatitis. RASONQUE received U.S. FDA approval on August 26, 2026.
Revolution Medicines (Nasdaq: RVMD) has begun treating patients in RASolute 309, testing RASONQUE plus zoldonrasib as first-line treatment for metastatic pancreatic cancer.
The global, randomized, open-label Phase 3 trial enrolls adults with RAS G12D pancreatic adenocarcinoma and compares the combination with gemcitabine and nab-paclitaxel. Its dual primary endpoints are progression-free survival, the time without cancer worsening, and overall survival. Secondary measures include tumor response, response duration, safety, tolerability, drug behavior in the body and patient-reported outcomes. RASONQUE is already FDA-approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Zoldonrasib remains investigational.
Revolution Medicines (RVMD) received U.S. FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic adenocarcinoma (PDAC).
The designation covers treatment-naïve metastatic PDAC in combination with this multiagent chemotherapy regimen and is based on preliminary Phase 1/2 RMC-GI-102 data in RAS mutant metastatic PDAC, where the regimen showed encouraging antitumor activity and a manageable safety profile. These results informed RASolute 303, an ongoing global Phase 3 trial evaluating RASONQUE as monotherapy and with chemotherapy versus chemotherapy alone in previously untreated metastatic PDAC, regardless of tumor RAS genotype. RASONQUE already has U.S. approval as an oral therapy for adults with metastatic PDAC after at least one prior systemic therapy or who are not candidates for multiagent systemic therapy, while first-line combination use remains investigational.